Diabetic Gastroparesis Clinical Trials Analysis 2025: Prokinetic Agents, Ghrelin Agonists, and Neuromodulators Target Gastric Motility Restoration and Symptom Relief | DelveInsight

DelveInsight's "Diabetic Gastroparesis - Clinical Trials Analysis, 2025" outlines a dynamic research landscape addressing the chronic, debilitating delays in gastric emptying associated with diabetes.

Current trials explore 5-HT4 receptor agonists, ghrelin receptor agonists, and selective dopamine D2/D3 antagonists aimed at improving motility and reducing nausea, bloating, and early satiety. Notably, relamorelin and metoclopramide analogs continue advancing through pivotal evaluation, while novel approaches such as vagal nerve stimulation and gastric peroral endoscopic myotomy (G-POEM) are being tested for refractory cases.

Primary endpoints across ongoing phase II-III studies include gastric emptying rate, Gastroparesis Cardinal Symptom Index (GCSI), and patient-reported quality-of-life outcomes. With multiple agents nearing registration milestones, the next few years may bring the first wave of differentiated therapies addressing both the symptomatic and physiological burdens of diabetic gastroparesis.

Interested in learning more about the current treatment landscape and the key drivers shaping the diabetic gastroparesis pipeline? Click here: https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Diabetic Gastroparesis Pipeline Report
• DelveInsight's diabetic gastroparesis pipeline analysis depicts a strong space with 6+ active players working to develop 8+ pipeline drugs for diabetic gastroparesis treatment.
• The leading diabetic gastroparesis companies include Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others are evaluating their lead assets to improve the diabetic gastroparesis treatment landscape.
• Key diabetic gastroparesis pipeline therapies in various stages of development include TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.
• In June 2025, Atmo Biosciences received FDA 510(k) clearance for its Atmo Gas Capsule System, allowing U.S. marketing and sales. The capsule aids in diagnosing gut motility disorders like gastroparesis and slow transit constipation. Clearance was based on positive results from a multi-site pivotal clinical study meeting all endpoints.
• In April 2025, Vanda Pharmaceuticals accused the FDA of deliberately delaying its request for a hearing on tradipitant's approvability for gastroparesis, blaming internal bureaucracy and recent leadership changes, including the appointment of Commissioner Dr. Martin Makary and agency staffing cuts.
• In January 2025, Vanda Pharmaceuticals accepted the FDA's hearing for the NDA of Tradipitant for gastroparesis, a digestive disorder with no new FDA-approved treatments in over 40 years. Current therapies are often ineffective, and studying new drugs is difficult due to symptom variability and placebo effects.

Request a sample and discover the recent breakthroughs happening in the diabetic gastroparesis pipeline landscape @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Gastroparesis Overview
Diabetic gastroparesis is a complication of diabetes that affects the stomach's ability to empty properly due to nerve damage, particularly to the vagus nerve. This delayed gastric emptying leads to symptoms such as nausea, vomiting, bloating, early satiety, and abdominal pain. It can cause poor blood sugar control because food digestion becomes unpredictable. Diagnosis typically involves gastric emptying studies and symptom evaluation. Management focuses on controlling blood glucose levels, dietary modifications, and medications to stimulate stomach motility or reduce symptoms. In severe cases, more advanced treatments or surgical options may be considered.

Find out more about diabetic gastroparesis medication @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Gastroparesis Treatment Analysis: Drug Profile
PCS-12852: Processa Pharmaceuticals
PCS-12852 is an innovative, highly selective 5-HT4 receptor agonist designed to treat gastrointestinal (GI) motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis. The drug is currently undergoing Phase II clinical trials for the treatment of Diabetic Gastroparesis.

NG101: Neurogastrx
NG101 is a potent and selective dopamine D2 receptor antagonist that is peripherally restricted. It is in Phase II clinical trials for treating Diabetic Gastroparesis. Preclinical studies from Neurogastrx have demonstrated that, in addition to its strong antiemetic effects, NG101 is also expected to significantly enhance gastric motility, making it a promising candidate for gastroparesis treatment.

Learn more about the novel and emerging diabetic gastroparesis pipeline therapies @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Gastroparesis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Diabetic Gastroparesis Pipeline Report
• Coverage: Global
• Key Diabetic Gastroparesis Companies: Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others.
• Key Diabetic Gastroparesis Pipeline Therapies: TD 1473, NG101, PCS-12852, THRX-149699, Camicinal, and others.

Dive deep into rich insights for drugs used for diabetic gastroparesis treatment; visit @ https://www.delveinsight.com/report-store/diabetic-gastroparesis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Diabetic Gastroparesis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diabetic Gastroparesis Pipeline Therapeutics
6. Diabetic Gastroparesis Pipeline: Late-Stage Products (Phase III)
7. Diabetic Gastroparesis Pipeline: Mid-Stage Products (Phase II)
8. Diabetic Gastroparesis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading market research and business consulting firm specializing in the life sciences industry. We provide pharmaceutical companies with tailored, end-to-end solutions to optimize their strategies and enhance business outcomes. With our subscription-based platform, PharmDelve, you can access a comprehensive range of healthcare and pharma market research reports, ensuring informed decision-making and sustained growth.

This release was published on openPR.